Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

Sponsor
Bristol-Myers Squibb
Study ID
NCT06504615
Status
Active Not Recruiting

Conditions

  • Esophageal Adenocarcinoma (EAC)
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Gastric Adenocarcinoma
  • Gastro-esophageal Junction Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroesophageal junction cancer.

Key Dates

Start date
Dec 10, 2024
Status verified
Apr 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
208 participants (actual)

Arms

  • Arm: Cohort 1
    Participants with a diagnosis of gastric adenocarcinoma, gastro-esophageal junction adenocarcinoma or esophageal adenocarcinoma
  • Arm: Cohort 2
    Participants with a diagnosis of untreated, unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma

Primary Outcome Measure

Overall survival (OS) [ Time Frame: Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36 ]

Related Studies